Skip to content

Research at St Andrews

The role of moxifloxacin in tuberculosis therapy

Research output: Research - peer-reviewArticle


Open Access permissions



Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate this treatment and discontinue therapy, increasing the risk of resistance. There is a growing tide of multidrug resistance and few effective antibiotics to tackle the problem. Since the turn of the millennium there has been a surge in interest in developing new therapies for TB and a number of new drugs have been developed. In this review the repurposing of moxifloxacin, an 8-methoxy-fluoroquinolone, for TB treatment is discussed. The evidence that underpins the development of this agent is reviewed. The results of the recently completed phase III trials are summarised and the reasons for the unexpected outcome are explored. Finally, the design of new trials that incorporate moxifloxacin, and that address both susceptible disease and multidrug resistance, is described.



Original languageEnglish
Pages (from-to)19-28
Number of pages10
JournalEuropean Respiratory Review
Issue number139
StatePublished - Mar 2016

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses

    Svensson, R. J., Aarnoutse, R. E., Diacon, A. H., Dawson, R., Gillespie, S. H., Boeree, M. J. & Simonsson, U. S. H. 7 Aug 2017 In : Clinical Pharmacology & Therapeutics. 103, p. 674-683 10 p.

    Research output: Research - peer-reviewArticle

  2. Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing

    Parcell, B. J., Oravcova, K., Pinheiro, M., Holden, M. T. G., Phillips, G., Turton, J. F. & Gillespie, S. H. Mar 2018 In : Journal of Hospital Infection. 98, 3, p. 282-288 7 p.

    Research output: Research - peer-reviewArticle

  3. OMNIgene.SPUTUM suppresses contaminants whilst maintaining Mycobacterium tuberculosis viability and obviates cold-chain transport

    Azam, K., Cadir, N., Madeira, C., Gillespie, S. H. & Sabiiti, W. 16 Feb 2018 In : ERJ Open Research. 4, 8 p., 00074-2017

    Research output: Research - peer-reviewArticle

  4. Detecting phenotypically resistant Mycobacterium tuberculosis using wavelength modulated Raman spectroscopy

    Baron, V. O., Chen, M., Clark, S. O., Williams, A., Dholakia, K. & Gillespie, S. H. 2018 Antibiotic Resistance Protocols. Gillespie, S. (ed.). New York, NY: Humana Press/Springer, p. 41-50 10 p. (Methods in Molecular Biology; vol. 1736)

    Research output: ResearchChapter

ID: 241406887